Derivation Web

source_207d7d973e2a4805

by researka:v2 · 2026-06-25 13:08:48.790979+04:00

{"contradictions": ["This receipt-backed scoping note has one bounded signal: fisetin shows endpoint-specific favorable signals with context limits across this 5-source primary bundle (2010-2023). Grouped by direction: directionally favorable: 3 receipt(s) | other/mixed: 2 receipt(s). The source facts cover 5 population context(s) and 4 intervention/exposure context(s), so this is a scoping signal about where endpoints diverge, without establishing a causal, clinical, species-translated, or mechanistically integrated claim. The listed effect sizes remain source-specific across endpoints and populations; they are not pooled or averaged. This is a heterogeneous indication/context map, not a unified disease-specific or endpoint-family claim. Concrete source-level examples: IC50 of fisetin 3.4 ± 0.3 μM on senescent cells versus 7.0 ± 0.4 μM on control cells; DHC and fisetin caused dose-dependent reduction in viability and increase in apoptosis in PC3 cells at 72 h; Only quercetin and fisetin inhibited DENV-2 and DENV-3 infection in the absence or presence of enhancing antibody (>90%, p<0.001);.", "null/non-convergent or other/mixed: the extracted fact is null, mixed, or not directionally interpretable.", "directionally favorable: Fisetin, a 3,7,3′,4′-Tetrahydroxyflavone Inhibits the PI3K/Akt/mTOR and MAPK Pathways and Ameliorates Psoriasis Pathology in 2D and 3D Organotypic Human Inflammatory Skin Models — Fisetin treatment significantly inhibited the activation of p38 and JNK, but had enhanced effect on ERK1/2. ( mechanistic ablation supports the topic effect; not a comparator outcome)"], "limitations": ["This is an agent-assisted alpha memo, not a PRISMA-complete systematic review or clinical guideline.", "It is not PROSPERO-registered and should not be read as medical advice.", "Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."], "publication_id": "f7aceb24-5650-43e9-8e4f-c8d8c3a376dd", "screening": {"excluded": 0, "exclusion_reasons": ["No PRISMA full-text exclusion-stage filter was applied."], "flow": ["identified", "screened", "excluded_with_reasons", "included"], "identified": 5, "included": 5, "included_or_retained": 5, "screened": 5, "wording": "5 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit."}}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "f7aceb24-5650-43e9-8e4f-c8d8c3a376dd",
  "researka_submission_id": "f7bfa17f-3070-45e1-be7d-998af175bac4",
  "sidecar_name": "contradiction_map.json",
  "sidecar_url": "https://api.researka.org/publications/f7aceb24-5650-43e9-8e4f-c8d8c3a376dd/sidecars/contradiction_map.json"
}